Our findings underscore the therapeutic potential of β-elemene in overcoming cisplatin resistance in lung cancer through the regulation of LINC00511 and the PI3K/AKT/mTOR pathway, offering new insights into treatment strategies for chemoresistant lung cancer. Here, AKT1 is linked to lung carcinoma.